Piper Sandler raised the firm’s price target on Black Diamond Therapeutics to $15 from $12 and keeps an Overweight rating on the shares. The company reported a meaningfully de-risking” data set for BDTX-1535 in relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer, the analyst tells investors in a research note. The firm believes that if this profile is confirmed, then BDTX-1535will have a role within second-line non-small cell lung cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Qualcomm eyes Intel deal while Apollo offers investment: Morning Buzz
- Morning Movers: Intel higher following report of Apollo investment interest
- Black Diamond Therapeutics Reports Promising BDTX-1535 Results
- Black Diamond announces initial Phase 2 data of BDTX-1535
- Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
Questions or Comments about the article? Write to editor@tipranks.com